In one breath
Adaptive Biotechnologies spent six straight years burning more cash than it earned, losing more than a dollar for every dollar of revenue as recently as 2023. The 10-Q for the quarter ended September 30, 2026 shows the company turned an adjusted operating profit for the first time. The stock trades at more than sixteen times annual sales, nearly double its own historical median, meaning the market is already pricing in a long winning streak. The open question is whether one profitable quarter is the start of that streak or a rest stop on a longer road.
What the filing actually says
For most of its public life, Adaptive was a company with a genuinely novel idea and a genuinely painful income statement. Its clonoSEQ test reads the genetic fingerprint of a patient’s cancer cells in the blood, a technique called minimal residual disease testing, or MRD, which lets oncologists check whether treatment is working without a painful tissue biopsy. The science was real. The losses were also real: the 10-K for fiscal year 2023 shows a net margin of negative 132%, meaning for every dollar the company collected, it spent more than two dollars.
Then something compounded. The 10-K for fiscal year 2025 shows revenue of $277 million, up 55% from the year before, while the net loss shrank by more than a hundred percentage points in two years. That is still a loss, but the direction of travel changed sharply.
The November 4, 2026 8-K detailing Q3 2026 results is where the story turns. Total revenue for the quarter reached $83.9 million. Adjusted EBITDA, a measure of operating earnings before accounting adjustments, came in solidly positive for the first time in the company’s public history. Free cash flow, the actual dollars left after running the business and investing in it, was also positive. For a company that spent years consuming cash the way a furnace consumes wood, generating cash is a structural change, not a rounding error.
The number that earns its place
The figure that testifies most clearly to the story is test volume. Adaptive delivered 39,587 clonoSEQ tests in Q3 2026, a 46% increase over the same quarter a year earlier. Think of it this way: if a hospital ran roughly 100 of these tests a week last year, it is now running about 146. That pace of adoption is what fills the revenue line without requiring the company to invent new products or win new categories. The existing test is simply being ordered more often, and each additional test costs less to deliver than the first, which is why margins improve as volume grows.
The company also raised its full-year 2026 MRD revenue guidance after the quarter closed. That is a guidance raise, not a guidance hold, which means management saw the results and moved the target up rather than down.
What compounds the picture, and what complicates it
The competitive backdrop is not quiet. As reported by Ion Genomics, Adaptive announced in June 2026 a plan to separate its MRD diagnostics business from its Immune Medicine research unit, the arm that maps T-cell receptor sequences for drug discovery. That split clarifies what the company is, but it also signals that the research side has not yet found a commercial model that justifies keeping it inside the same house.
Meanwhile, Natera received FDA approval in May 2026 for its Signatera CDx as the first personalized blood-based MRD companion diagnostic, and Guardant Health generated $335.0 million in Q2 2026 revenue from its liquid biopsy platform. The MRD testing market is real and growing, but it is no longer a field Adaptive occupies alone.
On the regulatory side, the FDA issued new final guidance on November 2, 2026 covering cellular and gene therapy products, updating a science- and risk-based framework that governs the kind of immune-based tools Adaptive’s research unit develops. Whether that guidance opens doors or raises the bar for the Immune Medicine segment is something the filing cannot yet answer.
The math and the mood
“The math” is what the filed numbers justify on their own terms. “The mood” is what the market is currently paying, regardless of those numbers. Our data shows Adaptive trading at 16.5 times annual sales, against its own historical median of 8.9 times. That gap means the market is paying nearly twice the company’s typical price-to-sales ratio, a multiple (the price tag per dollar of revenue) that assumes the profitability turn is not a single quarter but a durable new operating reality.
The math says a company that lost money for six years just produced its first positive cash quarter. The mood says that quarter is already priced as though the next several years look the same way. Those two readings can coexist, but they leave very little room for the story to disappoint.
Reading the numbers
- Q3 2026 revenue: $83.9 million. What it is: total sales for the three months ended September 30, 2026, per the 10-Q filed with the SEC. What it means here: annualized, this pace puts the company on track to exceed its own full-year 2025 revenue of $277 million, suggesting the growth rate is accelerating, not fading. Everyday version: a bakery that sold $277,000 worth of bread last year is now selling at a pace that implies more than $330,000 this year, and it just raised its own sales forecast.
- Adjusted EBITDA: $14.3 million positive. What it is: earnings before interest, taxes, depreciation, and amortization, adjusted for non-cash items, a measure of whether the core business generates cash before financing and accounting choices. What it means here: this is the first time this figure has been positive in the company’s public history, meaning the operating engine is no longer consuming fuel just to stay warm. Everyday version: a shop that spent years spending more than it took in finally closed a month where the register had money left after paying every bill.
- Price-to-sales ratio: 16.5 times, vs. historical median of 8.9 times. What it is: the stock price divided by annual revenue per share, our data computed from SEC filings and market prices. What it means here: investors are paying nearly double the company’s own historical norm per dollar of sales, placing this reading at the 81st percentile of its own decade-long range. Everyday version: a house that typically sells for eight times annual rent is currently listed at sixteen times, which is a bet that the rent is about to rise sharply and stay there.
Sources
- Adaptive Biotechnologies Q3 2026 8-K results, BioSpace
- 10-Q, quarter ended September 30, 2026, SEC EDGAR
- 10-K, fiscal year ended December 31, 2025, SEC EDGAR
- 10-K, fiscal year ended December 31, 2023, SEC EDGAR
- Adaptive separation of MRD and Immune Medicine, Ion Genomics
- Natera Signatera CDx approval and competitive landscape, Seeking Alpha
- FDA cell and gene therapy guidance, November 2026, OncoDailyy
